Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AVXL – Anavex Life Sciences Corp.

Float Short %

29.12

Margin Of Safety %

Put/Call OI Ratio

1.52

EPS Next Q Diff

-0.01

EPS Last/This Y

0.06

EPS This/Next Y

1.75

Price

4.01

Target Price

22

Analyst Recom

1.67

Performance Q

-55.75

Relative Volume

2.13

Beta

1.16

Ticker: AVXL



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13AVXL5.71.403.74203858
2025-11-14AVXL3.641.603.19239572
2025-11-17AVXL3.581.419.95228069
2025-11-18AVXL3.491.753.20261214
2025-11-19AVXL3.591.749.73263217
2025-11-20AVXL3.171.7919.77268197
2025-11-21AVXL3.251.666.09256763
2025-11-24AVXL3.071.560.55194441
2025-11-25AVXL3.451.540.68196053
2025-11-26AVXL3.871.511.11200556
2025-12-01AVXL3.831.501.88203997
2025-12-02AVXL3.681.501.17205145
2025-12-03AVXL4.571.500.97206533
2025-12-04AVXL4.451.521.14208530
2025-12-05AVXL4.391.510.71208698
2025-12-08AVXL4.341.511.80209426
2025-12-09AVXL4.411.500.67211742
2025-12-10AVXL4.071.491.83213966
2025-12-11AVXL4.11.501.79214958
2025-12-12AVXL4.021.521.45217469
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13AVXL5.68-7.1- -0.57
2025-11-14AVXL3.65-7.1- -0.57
2025-11-17AVXL3.58-7.1- -0.57
2025-11-18AVXL3.49-7.1- -0.57
2025-11-19AVXL3.60-7.1- -0.57
2025-11-20AVXL3.16-7.1- -0.57
2025-11-21AVXL3.24-7.1- -0.57
2025-11-24AVXL3.06-7.1- -0.57
2025-11-25AVXL3.46-7.1- -0.57
2025-11-26AVXL3.88-7.1- -0.57
2025-12-01AVXL3.8311.9- -0.52
2025-12-02AVXL3.6711.9- -0.52
2025-12-03AVXL4.5711.9- -0.52
2025-12-04AVXL4.4511.9- -0.52
2025-12-05AVXL4.4021.4- -0.48
2025-12-08AVXL4.3421.4- -0.48
2025-12-09AVXL4.4121.4- -0.48
2025-12-10AVXL4.0721.4- -0.48
2025-12-11AVXL4.1121.4- -0.48
2025-12-12AVXL4.0121.4- -0.48
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13AVXL0.001.5932.13
2025-11-14AVXL0.001.5932.12
2025-11-17AVXL0.002.0532.12
2025-11-18AVXL0.002.0532.12
2025-11-19AVXL0.002.0532.12
2025-11-20AVXL0.002.0532.12
2025-11-21AVXL0.002.0532.12
2025-11-24AVXL0.00-0.0332.12
2025-11-25AVXL0.00-0.0332.12
2025-11-26AVXL0.00-0.0334.63
2025-12-01AVXL0.00-0.0033.29
2025-12-02AVXL0.00-0.0033.29
2025-12-03AVXL0.00-0.0033.29
2025-12-04AVXL0.00-0.0033.29
2025-12-05AVXL0.00-0.0033.29
2025-12-08AVXL0.00-0.0533.29
2025-12-09AVXL0.00-0.0533.29
2025-12-10AVXL0.00-0.0529.12
2025-12-11AVXL0.00-0.0529.12
2025-12-12AVXL0.00-0.0529.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="AVXL" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-0.11

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

-0.05

Beta

1.16

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

20

Sentiment Score

10

Actual DrawDown %

87.3

Max Drawdown 5-Year %

-89.3

Target Price

22

P/E

Forward P/E

3.17

PEG

P/S

P/B

3.67

P/Free Cash Flow

EPS

-0.54

Average EPS Est. Cur. Y​

-0.48

EPS Next Y. (Est.)

1.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.13

Return on Equity vs Sector %

-75.8

Return on Equity vs Industry %

-60.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.89

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”AVXL” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”AVXL” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”AVXL” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”AVXL” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”AVXL” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”AVXL” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”AVXL” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Anavex Life Sciences Corp.
Sector: Healthcare
Industry: Biotechnology
Employees: 34
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
stock quote shares AVXL – Anavex Life Sciences Corp. Stock Price stock today
news today AVXL – Anavex Life Sciences Corp. stock forecast ,stock prediction 2023 2024 2025
marketwatch AVXL – Anavex Life Sciences Corp. yahoo finance google finance
stock history AVXL – Anavex Life Sciences Corp. invest stock market
stock prices AVXL premarket after hours
ticker AVXL fair value insiders trading